The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?
oleh: David E. Cohn, William S. Shimp
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2015-08-01 |
Deskripsi
No description available for this item.